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devoid of all viral genes cause less myocardial
inflammation compared with first-generation
adenovirus vectors
 Abstract Background First-generation, E1-deleted (E1) adenovirus
vectors currently used in cardiovascular gene therapy trials are limited by
tissue inﬂammation, mainly due to immune responses to viral gene products.
Recently, helper-dependent (HD; also referred to as “gutless”) adenovirus
vectors devoid of all viral coding sequences have been shown to cause low
inﬂammation when injected intravenously or into skeletal muscles. However,
HD vectors have not been evaluated in cardiovascular tissues.   Methods and
results HD and E1 vectors containing a cytomegalovirus-driven expression
cassette for the green fluorescent protein (GFP) gene were administered
intramyocardially to adult rats (n=54). GFP expression was measured by
ELISA at varying time intervals after gene transfer. HD and E1 vectors were
equally efﬁcient at transducing the myocardium. Tissue inﬂammation was
assessed by immunostaining for leukocytes and quantitative real-time RT-
PCR for cytokine mRNA expression. Monocyte/macrophages, CD4+ and
CD8+ lymphocytes inﬁltrating the myocardium were less abundant with HD
than E1 vectors. Transcripts levels for pro-inﬂammatory cytokines such as
IL-1, tumor necrosis factor-, and RANTES were decreased with HD vec-
tors. However, both vectors were associated with a decline in GFP expression
over time, although low-level expression was occasionally detectable 10 weeks
after HD vector administration. The two vectors transduced endothelial cells
in rat arteries (n=11) with comparable efﬁciencies. Vascular GFP expression
was not detectable at 10 weeks.   Conclusions HD vectors are as efﬁcient as
E1 vectors at transducing the myocardium and vascular endothelium, while
causing less myocardial inﬂammation. Thus, HD vectors may be superior to
earlier-generation adenovirus vectors for cardiovascular gene therapy appli-
cations.
 Key words High-capacity – helper-dependent – gutless – adenovirus –
heart
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Introduction
Efficiency and safety of gene transfer vectors are key
determinants of the clinical success of gene therapy.
Recombinant adenovirus vectors have been used in a
number of cardiovascular gene therapy studies and clin-
ical trials because they efﬁciently transduce both car-
diomyocytes and vascular cells in vivo [13, 36]. More-
over, adenovirus has been used safely as a life vaccine in
large populations, with no evidence of tumor induction.
First-generation adenovirus vectors deleted in the E1
early gene region (E1), with or without deletion of the
dispensable E3 early region (E3), are currently used in
gene therapy trials for coronary artery disease [16, 32].
However, usefulness of E1 and E1/E3 vectors is
similarly limited by tissue inﬂammation and short-lived
transgene expression. The E3 region contains open read-
ing frames (ORFs) for viral proteins that have anti-
apoptotic (e.g., E3-10.4K, E3-14.5K, E3-14.7K) and
immunomodulatory activities (e.g., E3-gp19K). Second-
generation adenovirus vectors carrying constitutive
expression cassettes for E3-14.7K or E3-gp19K have been
constructed. The E3-14.7K vector injected into the liver
mediated cytoprotective effects in mice, but did not affect
persistence of adenovirus DNA [15]. Similarly, we
showed reduced arterial inﬂammation after gene trans-
fer with an E3-gp19K vector in rabbits, but duration of
transgene expression was not significantly prolonged
[40]. E1 and E1/E3 vectors still contain E2 and E4
early adenoviral genes as well as late genes coding for
immunogenic proteins that induce cytotoxic immune
reactions [41, 42]. Consistent with a major role of
immune responses for short-lived transgene expression
with these vectors, we showed that treatment with
immunosuppressive drugs prolongs transgene expres-
sion in rat arteries [36].
Severe inﬂammatory reactions to adenovirus vectors
have been observed experimentally in the lung [5], liver
[42], brain [24], and heart [13]. Determinants of vector
toxicity include the vector backbone, the transgene prod-
uct itself, and the purity of vector preparations. Clinical-
grade purity is superior to that of vectors used in most
experimental studies. Adverse events directly related to
adenovirus vectors have been relatively rare in clinical
gene therapy trials [19]. However, a young patient died in
1999 soon after receiving adenovirus-based gene therapy
for treatment of partial ornithine transcarbamylase
(OTC) deﬁciency [20]. After receiving the highest dose of
the vector in the trial, the patient developed acute respi-
ratory distress syndrome and died two days later of mul-
tiple organ failure. The death was ascribed to an unusu-
ally strong inﬂammatory reaction to the vector.
As an experimental tool to assess the effect of
E1/E3 vectors in the presence of negligible production
of viral proteins, we previously used UV-irradiation,
which suppresses viral genes expression without sub-
stantially affecting the viral capsid. UV-irradiated aden-
ovirus vectors caused less inﬂammation and achieved
longer gene expression compared with non-irradiated
vectors in rat arteries in vivo [36]. More recently, aden-
ovirus vectors devoid of most or all viral coding
sequences (so-called “gutless” vectors) have been devel-
oped to minimize viral gene products [6, 12, 18, 22, 23, 30,
33]. Gutless vectors contain only the elements required
in cis for virus replication and packaging; hence, they
need co-infection with a helper virus that provides all
necessary viral proteins in trans for growth in vitro. Such
helper-dependent (HD) vectors injected intravenously
provided for efﬁcient and sustained transgene expres-
sion with decreased inﬂammation in the liver in mice
[8, 10, 27, 29, 34], dogs [8], and baboons [28]. Also, they
efﬁciently transduced skeletal muscles in mice [6, 25].
While the helper virus load of HD vector preparations
was of major concern with earlier production techniques
[1, 12, 26], improved systems based on a strong biologi-
cal selection against the helper virus have been developed
more recently [18, 30]. The biological selection is based
on the excision of the packaging signal, which is ﬂanked
by loxP sites, from the helper virus genome by Cre-
recombinase expressed by the producing cells during 
co-infection.
Low vector toxicity and sustained transgene expres-
sion are desirable features in most gene therapy strate-
gies. We therefore compared HD with ﬁrst-generation
adenovirus vectors in cardiovascular gene transfer mod-
els. The two vectors were equally efﬁcient at transducing
the myocardium and vascular endothelium; however,
myocardial inﬂammation was markedly attenuated with
HD vectors.
Methods
 HD vector system
The HD adenovirus vector system was provided by
Merck. Plasmid pC4HSUgfp contains the HD adenovirus
backbone, a cytomegalovirus (CMV)-driven expression
cassette for the green ﬂuorescent protein (GFP) reporter
gene, and stuffer DNA comprising fragments of human
genomic DNA selected by screening for the absence of
genes, repeat elements, and coding sequences, as
described [33]. Helper virus H14 contains a modified
packaging signal  ﬂanked by two loxP sites, and 2,902 bp
of human DNA, as described [34].
 HD vector rescue and purification
HD vector production was carried out in 293cre4 cells
expressing Cre-recombinase (Merck) [7]. Cells were
transfected in six-well plates with 3 µg of PmeI-digested
pC4HSUgfp using the FuGene reagent (Roche). Twelve
hours after transfection, 293cre4 cells were infected with
H14 helper virus at a multiplicity of infection (MOI) ≈ 5.
Wells that reached cytopathic effects at 48 h were selected
for propagation into passage 2. Cells were lysed by three
freeze/thaw cycles, and 2 ml of lysate were used to infect
a 10-cm dish of 293cre4 cells together with helper virus.
Infection cycles were repeated with increasing numbers
of cells until passage 6. At passage 6, HD vector from ﬁfty
15-cm plates was puriﬁed by triple CsCl banding.
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 HD vector titration and purity
The number of GFP gene-transducing particles in HD
vector preparations was determined as followed: 293 cells
were infected with serial dilutions of the HD vector
preparation. For comparison, 293 cells were infected at
different deﬁned MOIs with the E1 CMV-GFP vector to
generate a standard curve. Cells were incubated for 15
hours, and percentages of GFP-expressing cells were
determined by ﬂow cytometry. Helper virus was titered
by using an end-point dilution method in 96-well plates.
Plates were seeded with 3  103 293 cells that were
infected 24 hours later with serially diluted virus (range:
10–7–10–10). Infected cells were incubated for 14 days, and
cells with cytopathic effects were scored visually.
 First-generation adenovirus vector
The E1/E3 CMV-GFP adenovirus vector (referred to
as E1 vector) was constructed, propagated in 293 cells,
and puriﬁed by triple CsCl banding, as described [36].
 Myocardial gene transfer
Animal procedures were approved and carried out
according to institutional guidelines. Male Sprague-
Dawley rats (12–16 week-old; IFFA-Credo, L’Arbresle,
France) were anesthetized with i.p. ketamine/xylazine
(66.7/6.7 mg/kg), intubated, and mechanically ventilated.
A thoracotomy was performed in the 5th left intercostal
space, and vector containing solution (6  107 transduc-
ing units; TU, diluted in PBS to a ﬁnal volume of 25 µl)
was injected with a 32-gauge needle into the cardiac apex
and the apical portion of the anterior LV wall. Myocar-
dial GFP expression was determined by ELISA at varying
time intervals after gene transfer with HD (n=18) or E1
vectors (n=12). Injection of virus dilution buffer alone
served as a control (n=3). Additional rats (n=6) receiv-
ing low-dose (≈8  106 TU) HD vectors were sacriﬁced
at 1 and 2 weeks (n=3 each). In an attempt to reactivate
the CMV promoter within HD vectors, additional rats
(n=6) were re-thoracotomized 10 weeks after gene trans-
fer. Retinoic acid (RA; 100 nM) and trichostatin A (TSA;
32 nM) [14], or PBS (n=3 each), were injected into the
cardiac apex, and hearts were harvested 4 days later for
GFP-ELISA. Myocardial inﬂammation was assessed on
additional hearts receiving either HD vector, E1 vector
(2  107 TU each, diluted in virus dilution buffer to a ﬁnal
volume of 25 µl; n=3 and 4, respectively), or virus dilu-
tion buffer alone (n=3 each). Vectors were injected into
the apex and the apical portion of the anterior LV wall
under visual control (change in myocardial color).
Hearts were harvested 12 days later for RT-PCR for
cytokine expression analysis and for immunohisto-
chemistry of inﬂammatory cell inﬁltrates.
 GFP-ELISA
Hearts were excised, weighed, and homogenized. Total
cytoplasmic proteins were extracted using the NE-PER™
kit (Pierce). GFP concentrations in cardiac extracts were
measured by ELISA using React-bind™ anti-GFP coated
plates (Pierce). Brieﬂy, 100-µl samples in Assay Diluent
for OptEIA™ (PharMingen) were coated for 1 hour at RT.
Plates were washed and rabbit anti-GFP serum (IgG frac-
tion; Molecular Probes) was added (60 min), followed by
goat anti-rabbit biotinylated Ab (60 min), streptavidin-
HRP (45 min), and TBM substrate. The reaction was
stopped with 100 µl H2SO4 1.8 N. Plate reading was per-
formed at 450 nm. A standard curve (0.9–4,000 pg/ml)
with recombinant GFP (Molecular Probes) was made.
Background values in hearts injected with virus dilution
buffer were subtracted from those in transduced hearts.
 Immunohistological analysis
Immunohistochemistry was performed on cryosections
from hearts harvested 12 days after gene transfer. Brieﬂy,
rats were sacriﬁced by lethal pentobarbital injection, per-
fused with PBS, and the heart were excised. The cardiac
apex was kept on ice-cold PBS for RT-PCR, while a thick
myocardial slice directly adjacent to it was cut parallel to
the cardiac short axis and immediately frozen in OCT-
compound. This slice contained the distal part of the
needle track and the vector injection site, as visualized on
histological sections. In previous experiments with E1
adenovirus vectors using the same injection technique,
we had observed a wide distribution of GFP expressing
myocytes across this injected area, even at distant sites
from the needle track. The tissue sampling protocol used
in the present study was based on those previous obser-
vations. Inﬂammatory cells inﬁltrating the myocardium
were analyzed in three series of 8-µm sections per heart,
cut at fixed 100-µm steps starting from the apex.
Immunostainings were performed with the following
mAbs: anti-ED1-like (1C7) for monocyte/macrophages,
anti-TCR (R73), anti-CD8 (OX-8; all from PharMin-
gen), anti-CD4 (W3/25; Accurate Chemicals), irrelevant
mouse mAb MOPC-31C (PharMingen), and biotin-con-
jugated rabbit F(ab’)2 anti-mouse Ig (Jackson Immuno
Research Laboratories), followed by StreptABComplex/
HRP and DAB/H2O2 (Dako). Morphometric analysis was
performed in 6–8 microscopic ﬁelds (10X) per cardiac
section using the NIH-Image-1.62 program.
 Quantitative real-time reverse transcriptase-PCR
Hearts were excised and about 200 mg of apical myo-
cardium was placed in ice-cold PBS and cut into thin
slices, then submerged into RNAlater Stabilization
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Reagent. Total RNA was extracted with the Qiagen
RNeasy midi kit. DNase-treated RNA was used to gener-
ate cDNA, using the reverse transcriptase Omniscript
(Qiagen), random hexamer (Promega) and RNase
inhibitor (Roche). cDNA equivalent to 100 ng of total
RNA was used for each PCR reaction. Transcript levels
for cytokines were measured by quantitative real-time
PCR (Rotor-Gene 2000, Corbett Research), using the
SYBR-green dye. Constitutively expressed hypoxanthine
phosphoribosyltransferase (HPRT) was selected as
endogenous control to correct for potential variation in
RNA loading or efﬁciency of the ampliﬁcation reaction.
Primer sequences were as follows: interferon- (IFN-),
5’-tcatggccctctctggctgttac-3’ (sense) and 5’-caagaggag-
gctctttccttccatag-3’(antisense); interleukin-1 (IL-1),
5’-cttcaaatctcacagcagcatctcg-3’ (sense) and 5’-tccacggg-
caagacataggtagc-3’ (antisense); tumor necrosis factor-
(TNF-), 5’-ctgtgcctcagcctcttctcattc-3’(sense) and 5’-
ttgggaacttctcctccttgttgg-3’(antisense); transforming
growth factor- (TGF-), 5’-ctaatggtggaccgcaacaacg-
3’(sense) and 5’-tctggcactgcttcccgaatg-3’ (antisense);
RANTES, 5’-ccatatggctgcgacaccactc-3’ (sense) and 5’-
gcacacacttggcggttcctt-3’ (antisense); HPRT, 5’-ctcatg-
gactgattatggacaggactg-3’ (sense) and 5’-cagcgctttaatg-
taatccagcaggtc-3’ (antisense). The threshold cycle (CT)
was deﬁned as the fractional cycle number at which the
reported ﬂuorescence reached a deﬁned level [3]. Target
gene normalized to HPRT was expressed as CT (CT of
target gene minus CT of HPRT). For amplicons optimized
according to the manufacturer’s guidelines, ampliﬁca-
tion efﬁciency is typically close to one, i.e., product accu-
mulation increases twofold until the plateau phase is
reached. Thus, the ratio of target gene/HPRT could be
calculated by 2–CT. CT values obtained in the HD vec-
tor group were further normalized to the E1 vector
group by subtracting the CT values obtained in this
group from those obtained with HD vectors, yielding
CT [2].
 Arterial gene transfer
Arterial gene transfer was performed in male Sprague-
Dawley rats anesthetized with ketamine/xylazine. The
left carotid artery was surgically exposed, and a silicone
catheter was introduced through an arteriotomy of the
external carotid artery. Virus vector stocks were diluted
to a ﬁnal concentration of 7  108 TU/ml with M-199
medium supplemented with 1 mg/ml rat albumin frac-
tion V (Sigma). Virus-containing medium was instilled
into the isolated carotid segment, where it remained for
20 minutes. Blood ﬂow was then reestablished through
the common and internal carotid arteries.
 Histological analysis of arteries
Rat carotid arteries were harvested 5 days (n=4 for each
vector) or 10 weeks after gene transfer (n=3 for HD vec-
tor), rinsed in PBS, and snap-frozen in OCT compound.
Ten arterial sections per vessel, cut at a ﬁxed distance of
100 µm from each other, were examined for GFP express-
ing cells by direct ﬂuorescence microscopy. Correspond-
ing sections were stained with hematoxylin/eosin.
 Statistical analysis
Data are shown as median values (range), unless stated
differently. Differences in peak GFP levels (1 week after
gene transfer) and in cytokine mRNA expression
between HD and E1 vectors were compared with the
Wilcoxon test (rank sums). Differences in myocardial
inflammatory cell infiltrates among the three experi-
mental groups (HD vectors, E1 vectors, and buffer solu-
tion alone) were compared with the Kruskal-Wallis test
(rank sums). The Wilcoxon test was used for 2 group-
analysis of immunohistochemical data. p-values <0.05
were considered to be statistically signiﬁcant.
Results
 HD vector preparation
Transducing titers for HD and E1 vector stock prepa-
rations were 2  109 and 3  1010 TU/ml, the number of
virus particles were 3.5  1010 and 3  1011 particles/ml,
with calculated virus particles/TU ratios of 17.5 and 10.0,
respectively. Purity of HD vector preparations was
99.8%.
 HD vectors efficiently transduce rat myocardium
HD vectors efficiently transduced rat myocardium in
vivo. Cardiac myocytes accounted for the majority of
GFP expressing cells, as identiﬁed based on their charac-
teristic striated morphology (Fig. 1). At varying time
intervals after high-dose (7  107 TU) vector injection,
GFP concentrations in cardiac extracts were measured by
ELISA and expressed as median values (range) normal-
ized per gram of tissue. One week after gene transfer, car-
diac GFP concentrations were comparable with HD and
E1 vectors: 59.2 ng (45.8–67.1 ng) vs. 55.3 ng (41.2–58.5
ng; NS). However, GFP levels fell ≈ 6-fold to 9.2 ng
(1.8–18.2 ng) 2 weeks after gene transfer with HD vectors
(Fig. 2B). Using low-dose (8  106 TU) HD vectors, GFP
levels were 0.9 ng (0.2–2.8 ng) and 1.2 ng (0–32.8 ng) at
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in a dose-dependent manner. However, transgene
expression is short-lived in most cases. In the subgroup
of mice re-thoracotomized 10 weeks after gene transfer
with HD vectors, signiﬁcant GFP levels (0.3 and 2.8 ng)
were detected in 2 out of 3 hearts injected with RA+TSA,
but in none of those injected with PBS. Modest pharma-
cological reactivation of the CMV promoter driving
transgene expression may occur in some hearts late after
gene transfer; however, our data are not conclusive in
this regard.
 HD vectors are associated with attenuated cellular
inflammation
To evaluate myocardial inflammation, we immunos-
tained sections from hearts injected with HD vectors,
E1 vectors or buffer solution alone for multiple inﬂam-
matory cell markers (Fig. 3A). A small area of disturbed
tissue structure, corresponding to a small ﬁbrotic lesion
induced by intramyocardial needle injection, along with
GFP-positive cells (Fig. 1) documented appropriate
tissue sampling. Significant differences among the 3
experimental groups were found for ED-1–like+, CD8+,
and TCR+ cells (p<0.05 for each marker using the
Kruskal-Wallis test). HD vectors caused markedly less
monocyte/macrophage and T-cell inﬁltrates than E1
vectors, as evidenced by ≈5-fold decreased ED-1–like+
myocardial cell population (6.3 ± 3.9% vs. 32.4 ± 5.1%),
≈ 7-fold decreased CD4+ population (5.9 ± 3.5 % vs.
43.1 ± 4.2 %), ≈ 5-fold decreased TCR+ population
(5.7 ± 3.4 % vs. 30.1 ± 4.4 %), and ≈5-fold decreased
CD8+ population (5.5 ± 3.4% vs. 29.4 ± 4.8%) (p<0.05
for each marker using the Wilcoxon test; Fig. 3B).
TCR+ cells, but not ED-1–like+, CD8+ and CD4+ cells,
were more abundant with HD vectors compared with
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Fig. 1 Photomicrograph showing GFP expression in rat cardiomyocytes after HD
vector-mediated in vivo gene transfer. The GFP expressing cells were readily iden-
tified as myocytes based on the characteristic morphology (original magnification,
500x)
Fig. 2 A GFP content in cardiac extracts
at varying time intervals after gene
transfer with E1 vectors (determined
by ELISA).  B GFP content in hearts
injected with HD vectors.  C GFP content
in hearts injected with RA/TSA or PBS
10 weeks after HD vector injection,
4 days before analysis. Individual (cir-
cles) and median values (horizontal
lines) are shown for each time point.
Peak GFP levels with the two vectors
were observed 1 week after gene trans-
fer and were comparable to each other;
however, they rapidly declined there-
after. Intramyocardial RA/TSA adminis-
tration at 10 weeks was associated with
detectable GFP expression in 2 out of 3
hearts injected with HD vectors. Data
are nanograms GFP normalized for 1
gram of tissue (logarithmic scale)
1 and 2 weeks, respectively. Using E1 vectors, cardiac
GFP levels were 50.7 ng (1.0–73.1 ng) and 0.9 ng (0.8–1.1
ng) at 2 and 4 weeks, respectively (Fig. 2A). Ten weeks
after gene transfer, GFP was barely detectable (threshold
≈0.05 ng) in most hearts, with the exception of one heart
(1.6 ng) in the HD vector group. These results indicate
that HD vectors efﬁciently transduce adult myocardium
buffer solution alone. These results indicate that HD vec-
tors cause markedly less cellular inﬂammation than E1
vectors, although they induce some residual, low-level
inﬂammation.
 HD vectors are associated with attenuated expression
of pro-inflammatory cytokines
mRNA expression of several cytokines was determined
by real-time RT-PCR in hearts injected with HD or E1
vectors (Fig. 4). HD vectors induced significantly
decreased transcript levels (expressed as 2–CT, normal-
ized to E1 vectors) for the pro-inﬂammatory cytokines
IL-1 (0.01; range, 0–0.01; p<0.05), TNF- (0.01; range,
0 – 0.02; p < 0.05), and the RANTES chemokine (0.04;
range, 0.03–0.05; p<0.05). Transcripts of IFN- (median
value) were reduced by ~90% with HD compared with
E1 vectors, but differences were below the signiﬁcance
level. Transcripts of TGF- were slightly (not signifi-
cantly) increased with HD compared with E1 vectors.
Enhanced expression of TGF- as an immunomodula-
tory molecule may inhibit tissue inﬂammation.
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Fig. 3 A Inflammatory cells infiltrating the myocardium after gene transfer with
E1 (upper row) and HD vectors (middle row). Control hearts received virus dilu-
tion buffer (PBS; lower row). Immunostainings for CD4, ED1-like, CD8, and TCR
(columns from the left to the right; original magnification, 100x).  B Quantitative
analysis of inflammatory cell markers. Macrophages and T cells were less abundant
with HD compared with E1 vectors. Data are mean percent positive-staining
myocardial areas ±SD. § = p<0.05 with the Wallis-Kruskal test (3 group-analysis);
* = p<0.05 with the Wilcoxon test (rank sums; 2 group-analysis)
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 HD vectors transduce vascular endothelium in vivo
HD vectors were tested in rat carotid arteries in vivo.
Both HD and E1 vectors selectively transduced
endothelial cells in uninjured vessels (Fig. 5; transduc-
tion rates ≈3–5% with either vector). A dose-dependent
increase in transduction rates (up to ≈ 30 %) was
observed with E1 vectors (data not shown). However,
this aspect could not be assessed with HD vectors due to
the lower titer of these vectors’ preparations, which
reﬂects current limitations of vector production tech-
niques. GFP expressing endothelial cells were not
detectable 10 weeks after gene transfer.
Discussion
First-generation adenovirus vectors have been used in
many cardiovascular studies and in phase I/II gene ther-
apy trials for ischemic heart disease and peripheral vas-
cular disease. A large body of experimental evidence,
along with the rare occurrence of adverse events in clin-
ical trials suggest that these vectors are associated with
signiﬁcant toxicity. Immune responses to viral proteins
produced by ﬁrst-generation E1 and E1/E3 adeno-
virus vectors cause tissue inﬂammation with consequent
clearance of transduced cells. Recently, improved
adenovirus vectors devoid of all viral coding sequences
(“gutless” vectors) have been developed.
In the present study, we show that HD and E1 vec-
tors are equally efficient, on a virus particle-basis, at
transducing adult myocardium and arterial endothelium
in vivo. Myocardial gene transfer was dose-dependent.
HD vectors caused markedly less myocardial inﬂamma-
tion than E1 vectors, as reﬂected by lower numbers of
monocyte/macrophages, total T cells, CD4+ and CD8+
lymphocytic infiltrates, as well as decreased mRNA
expression for pro-inﬂammatory cytokines such as IL-
1, TNF-, and RANTES. These results are in good
agreement with previous data showing modest to negli-
gible HD vector toxicity in the liver and skeletal muscle
[6, 8, 10, 25, 27–29, 34]. However, myocardial GFP
expression was short-lived in the present study, even
though low-level expression was occasionally detectable
(1 heart without and 2 with late RA/TSA injection) 10
weeks after HD vector administration. These ﬁndings are
consistent with a previous report showing early and com-
plete loss of transgenic -galactosidase expression,
accompanied by predominantly CD4+ and CD8+ lym-
phocytic inﬁltrates and loss of vector DNA, after HD vec-
tor-mediated LacZ gene transfer into mouse skeletal
muscle [6]. The same vector injected into transgenic mice
constitutively expressing -galactosidase achieved per-
sistent expression of exogenous -galactosidase, with no
evidence of tissue inﬂammation. Furthermore, adenovi-
ral expression of human erythropoietin was lost in mice,
whereas exogenous mouse erythropoietin was expressed
for extended periods of time [38]. Similar observations
have been made using GFP as a reporter protein [37],
indicating that immune responses to GFP or -galac-
tosidase can extinguish transgene expression. In the
present study, similar peak GFP levels for the two vectors
were observed at 1 week, but GFP levels at 2 weeks tended
to be higher (not signiﬁcant) with E1 compared with
HD vectors. Thus, the possibility that stronger immune
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Fig. 4 Cytokine mRNA expression in cardiac extracts with HD vectors normalized
for cytokine expression with E1 vectors. Data are 2–CT (values above and below
the dotted line = 1.0 show induced and inhibited cytokine expression, respectively,
using HD vectors relative to that with E1 vectors (logarithmic scale; * = p<0.05)
Fig. 5 HD vector-mediated GFP gene transfer into a rat artery. Two GFP-expressing
endothelial cells are visualized by direct fluorescence microscopy (original magni-
fication, 500x)
responses to higher GFP levels at 2 weeks induced more
intensive tissue inﬂammation in the HD-vector group
cannot be discarded. In apparent contrast to an
immunogenic role for GFP, we previously reported long-
term persistence of AAV-mediated GFP expression in
mouse myocardium with no apparent inﬂammation [39].
These ﬁndings can be reconciled by experimental data
showing that different vectors may induce distinct
immune responses to the same transgenic protein. For
instance, gene transfer of mouse coagulation factor IX in
mice with hemophilia B induced cytoxic T lymphocytes
to this factor using adenovirus, but not AAV, vectors
[11]. A potential explanation is that adenovirus, unlike
AAV, efﬁciently infects dendritic cells, which play a key
role in antigen presentation, triggering cytoxic immune
responses [21]. Also, several components of HD vectors
including the transgene promoter and stuffer DNA affect
their in vivo performance [33, 35]. For instance, a human
CMV promoter, but not a phosphoglycerate kinase
(PGK) promoter, within HD vectors resulted in an anti-
body response against human alpha-1 antitrypsin in
mice [35]. Again, this observation was interpreted to
mean that the generation of antibody responses against
foreign antigens is induced by the use of a promoter that
expresses the antigen in dendritic cells.
Recently, we and others reported on myocardial gene
transfer using novel lentivirus vectors derived from
human immunodeﬁciency virus-1 (HIV-1) [13, 43]. In
our previous study [13], lentivirus vectors containing a
CMV-driven GFP expression cassette were tested in the
same experimental model used in the present study;
hence, observations made in the previous study may be
of interest for the interpretation of the present data.
Using lentivirus vectors, we previously found a similar
early decline in myocardial GFP expression compared
with E1 adenovirus vectors, despite the fact that lentivi-
ral DNA is integrated into the host cell chromatin,
whereas adenoviral DNA is not. Loss of integrated
lentivirus DNA paralleled the early loss of GFP expres-
sion, supporting immune-mediated clearance of trans-
duced cells as the underlying mechanism. This may also
hold true for the progressive extinction of GFP expres-
sion with HD vectors, although myocardial inﬂammation
observed with these vectors was milder than with lentivi-
ral vectors (data not shown) [13]. Several factors includ-
ing capsid toxicity, cell-derived proteins that co-purify
with vector particles, helper virus particles in HD vector
preparations, and needle injury may account for the
residual, low-level tissue inflammation observed with
HD vectors. The main difference between lentivirus and
HD vectors was that lentiviral GFP expression stabilized
after week 4 and was still detectable at week 10, whereas
HD vector-mediated expression was only rarely
detectable at this late time point, consistent with the
intrinsic instability of episomal (i. e., non-integrated)
adenovirus DNA.
Intracellular mechanisms may lead to speciﬁc shut off
in gene expression or elimination of the vector genome
without destruction of infected cells [33], as described for
hepatitis B virus in chimpanzees [17]. Transcriptional
silencing is a frequent cause of shut off in gene expression
using constitutive viral promoters [9, 14]. The transcrip-
tional activity of the human CMV promoter is regulated
by several cytokines [31], some of which were induced, to
different extents, by adenovectors in the present study. In
an attempt to reactivate the CMV promoter within HD
vectors, we injected RA and TSA [9, 14] into the heart in
a small subgroup of rats 10 weeks after gene transfer.
Four days later, GFP expression was detectable in 2 out
of 3 hearts receiving RA/TSA, but in none of those
injected with buffer solution at 10 weeks (Fig. 2C). This
observation suggests, but does not prove, that transcrip-
tional silencing may play a contributory role in loss of
myocardial GFP expression with HD vectors.
Finally, we tested HD vectors in rat carotid arteries.
Titer-matched HD and E1 vectors were equally efﬁcient
at transducing vascular endothelium in vivo. However,
numbers of endothelial cells expressing GFP at a histo-
logically detectable level were relatively modest using the
available vector concentrations. Differences in large-
scale production techniques between HD and E1 vec-
tors prevented testing of more concentrated HD vectors
in this model. Higher-titer HD vectors may be needed to
further improve endothelial transduction in vivo.
From a clinical point of view, the preeminence of HD
vectors over earlier generation adenovirus vectors
should be considered within the framework of available
clinical data. A recent report summarizing safety aspects
of E1/E3 adenovirus vectors in several different gene
therapy trials (n=90 patients) showed no death directly
related to the vectors, and a 0.7% total incidence of major
adverse events linked to them [19]. In three gene therapy
trials for coronary artery disease, patients received up to
4  1010 particle units of intramyocardial E1/E3 ade-
novirus vector expressing vascular endothelial growth
factor-121 (VEGF-121) [32], or up to 3.3  1010 TU of
intracoronary E1 vector expressing ﬁbroblast growth
factor-4 (FGF-4) [16]. In the VEGF-121 gene trial (phase-
I) [32], there were 2 perioperative deaths unrelated to
adenovirus administration. In one of them, autopsy
revealed no abnormalities in the myocardial territory
treated with the vector. No perioperative increase in
myocardial enzymes, and no ECG or echocardiographic
changes were observed in this trial. In the FGF-4 gene
trial (phase-I), transient fever occurred in 3 patients
receiving the highest dose of the vector, but no severe
adverse events were related to it. In the FGF-4 gene
phase-II trial [16], there were no deaths, myocardial
infarction, or myocarditis, but transient fever and rise in
serum bilirubin occurred in one patient in the adeno-
virus group. A tendency toward a functional improve-
ment was observed in the treated group. Obviously, clin-
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ical manifestations may not adequately reﬂect mild to
moderate myocardial inflammation, and histological
analysis was not feasible in most cases. Thus, despite
clinical evidence that E1 vectors were relatively well
tolerated in cardiovascular trials, HD vectors may be
safer for future applications.
In conclusion, HD vectors are as efﬁcient as earlier
generation adenovirus vectors in cardiovascular gene
transfer models. However, they are substantially less
toxic, at least under this study’s experimental conditions.
Moreover, HD vectors offer a large capacity to accom-
modate large DNA fragments, potentially allowing the
simultaneous expression of several genes, genomic DNA,
large cDNAs, and the introduction of large regulatory
DNA regions. Recently, it has been shown that the use of
genomic DNA may be advantageous over small cDNA
expression cassettes for gene transfer-based strategies
[35]. Thus, high-capacity adenovirus vectors may be
useful tools in the armamentarium of cardiovascular
gene therapy.
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